What mRNA is Good For, And What It Maybe Isn’t
By Derek Lowe,
Science Magazine
| 06. 29. 2021
The huge success of the mRNA vaccination platform during the pandemic has set a lot of people to thinking about what comes next. Moderna and BioNTech, of course, have been thinking this way for quite some time. But Sanofi now says that they’ll be investing large amounts into the technology, and this previously hadn’t been a big priority for them. There are others as well. So let’s step back a little and look at what mRNA can do and what it can’t.
Therapeutic mRNAs
The first distinction is between vaccines and therapeutics. It’s hard to remember now, but Moderna did not really start out as a vaccine company – they were going to make mRNA-based therapeutics, and there are some key differences. It’s an exciting idea to reach into the body and tell particular cells to start making particular proteins (of your choice) by sending mRNA messages into them. You can think of a lot of possibilities, but there are a lot of difficulties along the way to realizing that.
For one, you’re not taking advantage of the memory that...
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...